About DermR Health

DermR Health is developing a world-first non-invasive pathway for diagnosing skin cancer, addressing global inefficiencies where more than 60% of skin biopsies are benign and avoidable. By combining a novel skin microsampling device with its proprietary Skin Cancer Genetic Test, DermR Health gives clinicians a new non-invasive option to help rule out benign lesions earlier.

🎯 The Problem

Skin cancer diagnosis still relies on biopsy or excision because clinicians lack an accurate, non-invasive way to rule out benign lesions before cutting the skin. For many people, that means going through the anxiety of waiting, the discomfort of a biopsy and scarring, only to later be told the result was benign. More than 60% of skin biopsies prove benign, representing over 1.1M benign skin biopsies in Australia last year alone. This creates a high-volume invasive workload that strains primary care, dermatology and pathology capacity, and delays diagnosis across the care pathway. With rising skin cancer incidence globally and ongoing workforce constraints, system pressures are set to worsen. This creates a clear need for a scalable diagnostic pathway that reduces avoidable surgical sampling without compromising diagnostic confidence.

💡 The Solution

DermR Health gives clinicians a new way to test suspicious skin lesions without requiring a biopsy. The DermR® Patch uses a novel microneedle patch to collect viable skin cells, which can be analysed by any pathology providers using DermR Health's proprietary Skin Cancer Genetic Test. The test helps rule out benign lesions and, where cancer is detected, uniquely identifies whether it is melanoma, BCC or SCC. This supports earlier, more informed triage and treatment decisions, including whether to proceed with surgery, monitoring or selected non-surgical treatment pathways. By shifting appropriate cases from a high-volume, surgery-first pathway into a scalable molecular triage model, DermR has the potential to improve access, reduce system burden and support earlier, more equitable skin cancer diagnosis.

📊 Market & Funding

👥 Team

Stefan Mazy

CEO Founder

Stefan Mazy is a genomics entrepreneur and innovator with more than a decade of experience in developing and commercialising diagnostic technologies. He is the inventor of the DermR® Patch, a non-invasive microneedle skin sampling device, and Founder and CEO of DermR Health. He previously founded SkinDNA®, the world’s first direct-to-consumer skin genomics test, which scaled to more than 20 countries and continues to be used in clinics worldwide.

in

Dr Rebecca Saunderson

Chief Medical Officer

Dr Rebecca Saunderson is DermR Health’s Chief Medical Officer, bringing specialist dermatology, clinical research and medtech founder experience. She is a Fellow of the Australasian College of Dermatologists and Staff Specialist Dermatologist at Royal North Shore Hospital. At DermR Health, she supports clinical strategy, evidence generation and real-world adoption of the DermR® Patch.

in

Natalie Barber

Clinical Trials Manager

Natalie Barber is a clinical trials and governance specialist with more than 20 years’ experience across Australia and the UK. She brings deep expertise in regulatory compliance, clinical operations and trial governance, supporting the development and validation of the DermR® Patch to a high clinical and quality standard.

in